Aytu Biopharma Inc (OQ:AYTU)

Feb 14, 2024 04:05 pm ET
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
DENVER, CO / ACCESSWIRE / February 14, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 second quarter.
Feb 07, 2024 04:15 pm ET
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period ended December 31, 2023, after the market close on Wednesday, February 14, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, February 14, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer section.
Jan 23, 2024 09:00 am ET
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
DENVER, CO / ACCESSWIRE / January 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference taking place virtually on February 1, 2024.
Dec 06, 2023 07:00 am ET
Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now
EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 65th Emerging Growth Conference on December 6th and 7th, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors,...
Nov 30, 2023 08:00 am ET
Nov 14, 2023 04:05 pm ET
Nov 07, 2023 04:15 pm ET
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023
DENVER, CO / ACCESSWIRE / November 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its first quarter of fiscal year 2024 for the period ended September 30, 2023, after the market close on Tuesday, November 14, 2023. The Company has scheduled a conference call that same day, Tuesday, November 14, 2023, at 4:30 pm ET, to review the results.
Oct 26, 2023 08:00 am ET
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
U.S. Food & Drug Administration Approval of the Prior Approval Supplement (PAS) Enables Transfer of Cotempla Production to Contract Manufacturer
Oct 09, 2023 04:15 pm ET
Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023
ENGLEWOOD, CO / ACCESSWIRE / October 9, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023.
Sep 29, 2023 09:31 am ET
Thinking about buying stock in Blue Apron Holdings, OceanPal, OPKO Health, Bionomics, or Aytu Biopharma?
NEW YORK, Sept. 29, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APRN, OP, OPK, BNOX, and AYTU.
Sep 21, 2023 08:25 pm ET
Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023
ENGLEWOOD, CO / ACCESSWIRE / September 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its fourth quarter and fiscal year ended June 30, 2023, after the market close on Wednesday, September 27, 2023. The Company has scheduled a conference call that same day, Wednesday, September 27, 2023, at 4:30 pm ET, to review the results.
Sep 13, 2023 08:00 am ET
Aytu BioPharma to Present at LD Micro Main Event XVI Conference
ENGLEWOOD, CO / ACCESSWIRE / September 13, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, and CFO, Mark Oki, will be will be participating in the LD Micro Main Event XVI Conference, being held on October 3-5, 2023, at Luxe Sunset Boulevard Hotel in Los Angeles.
Aug 08, 2023 09:15 am ET
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the release of a thematic report that examines small market cap pharmaceutical companies based on revenue growth and valuation. The report: Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline examines that represents the top 0.1 percentile of small pharmaceutical growth companies.
Jul 31, 2023 08:00 am ET
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority
After the completion of local regulatory approvals, Aytu anticipates exporting to Medomie both of its novel, orally disintegrating, extended-release tablets for the treatment of ADHD
Jul 10, 2023 08:00 am ET
Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
Company Expects a Six-Month Review of the Prior Approval Supplement Submission by the U.S. Food & Drug Administration Which, if Approved, Enables the Transfer of Cotempla Production to Contract Manufacturer
Jun 14, 2023 08:00 am ET
Aytu to Participate in the Maxim Group Virtual Healthcare Conference
ENGLEWOOD, CO / ACCESSWIRE / June 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced Joshua Disbrow, Aytu's Chief Executive Officer, will participate in a company discussion and host one-on-one meetings with investors at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, taking place virtually from June 20-22, 2023.
Jun 13, 2023 01:45 pm ET
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market
Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon Closing
Jun 09, 2023 08:00 am ET
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director
ENGLEWOOD, CO / ACCESSWIRE / June 9, 2023 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its equity offering co-led by Nantahala Capital Management and Stonepine Capital Management with participation by Armistice Capital of (i) 1,743,695 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 430,217 shares of its common stock ("Pre-Funded Warrants"), and (ii) accompanying Tranche A and Tranc
May 11, 2023 04:05 pm ET
Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results
ENGLEWOOD, CO / ACCESSWIRE / May 11, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced financial and operational results for the quarter ended March 31, 2023.
May 04, 2023 04:30 pm ET
Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023
ENGLEWOOD, CO / ACCESSWIRE / May 4, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for its third quarter fiscal year 2023, ended March 31, 2023, after the market close on Thursday, May 11, 2023. The Company has scheduled a conference call that same day, Thursday, May 11, 2023, at 4:30 pm ET, to review the results.
May 01, 2023 08:00 am ET
Aytu BioPharma Subleases a Portion of Its Manufacturing Facility
ENGLEWOOD, CO / ACCESSWIRE / May 1, 2023 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, entered into an agreement with AMT Manufacturing Solutions, LLC ("AMTMS"), a newly established, full service Contract Manufacturing Organization ("CMO"), to sublease 22,909 square feet of Aytu's Grand Prairie, TX manufacturing facility. This sublease represents over 30% of the Compa
Apr 27, 2023 08:00 am ET
Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer
U.S. Food & Drug Administration Approval of Prior Approval Supplement Enables Transfer of Adzenys Production to Contract Manufacturer in 2023
Feb 21, 2023 04:10 pm ET
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023
Second Consecutive Quarter of Positive Adjusted EBITDA
Feb 21, 2023 03:00 pm ET
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023
ENGLEWOOD, CO / ACCESSWIRE / February 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for the quarter ended December 31, 2022, after the market close today, Tuesday, February 21, 2023. The Company has also scheduled a conference call for today, Tuesday, February 21, 2023, at 5:00 pm ET, to review the results.
Feb 14, 2023 08:00 am ET
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results
ENGLEWOOD, CO / ACCESSWIRE / February 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, has announced the delayed filing of its Form 10-Q for its second quarter fiscal year 2023, ended December 31, 2022 to allow for additional assessment and management review time on an accounting matter. The matter is related to the accounting for warrants issued in previous financings and we
Feb 07, 2023 08:00 am ET
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023
ENGLEWOOD, CO / ACCESSWIRE / February 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for its second quarter fiscal year 2023, ended December 31, 2022, after the market close on Tuesday, February 14, 2023. The Company has scheduled a conference call that same day, Tuesday, February 14, 2023, at 4:30 pm ET, to review the results.
Jan 25, 2023 08:00 am ET
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance
ENGLEWOOD, CO / ACCESSWIRE / January 25, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq's minimum bid price requirement.
Jan 24, 2023 08:00 am ET
Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31
ENGLEWOOD, CO / ACCESSWIRE / January 24, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced that Josh Disbrow, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023.
Jan 10, 2023 08:00 am ET
Jan 05, 2023 04:01 pm ET
Aytu BioPharma Announces 1-for-20 Reverse Stock Split
ENGLEWOOD, CO / ACCESSWIRE / January 5, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced a 1-for-20 reverse stock split of its outstanding common stock, effective at 12:01 a.m. Eastern time on January 6, 2023. Beginning tomorrow, January 6, 2023, the Company's common stock will trade on a split-adjusted basis.
Nov 30, 2022 08:00 am ET
Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect
Adzenys XR-ODT Total Prescription (TRx) Unit Growth Driven by a Combination of Continued Sales Force Execution, Leveraging of the Aytu RxConnect Patient Support Program, and a Positive Response to the Adderall® XR Supply Disruption
Nov 22, 2022 04:05 pm ET
Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
ENGLEWOOD, CO / ACCESSWIRE / November 22, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced today that the Company received written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq"), granting the Company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq List
Nov 16, 2022 08:00 am ET
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso
ENGLEWOOD, CO / ACCESSWIRE / November 16, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced the passing of Michael Macaluso, Co-Founder and founding board member of Aytu.
Nov 14, 2022 04:05 pm ET
Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023
Record Quarterly Net Revenue of $27.7 Million Driven by 34% Growth in Rx Segment
Nov 07, 2022 04:01 pm ET
Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022
ENGLEWOOD, CO / ACCESSWIRE / November 7, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for its first quarter fiscal year 2023, ended September 30, 2022, after the market close on Monday, November 14, 2022. The Company has scheduled a conference call that same day, Monday, November 14, 2022, at 4:30 pm ET, to review the results.
Oct 25, 2022 08:00 am ET
Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term Loan
Amendment of Secured Loan Agreement Extends Interest-Only Period to January 2024
Oct 13, 2022 08:00 am ET
Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs
Following a corporate review, Aytu BioPharma is indefinitely suspending clinical development and removing expenses related to AR101/enzastaurin, Healight, and NT0502, and focusing on revenue growth and near-term cash flow generation
Sep 27, 2022 04:05 pm ET
Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue
Record fourth quarter and fiscal year net revenue driven by strong growth in Prescription segment
Sep 20, 2022 08:00 am ET
Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022
ENGLEWOOD, CO / ACCESSWIRE / September 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, will report financial results for its fourth quarter and fiscal year ended June 30, 2022, after the market close on Tuesday, September 27, 2022. The Company has scheduled a conference call that same day, Tuesday, September 27, 2022, at 4:30 pm ET, to review the results.
Sep 14, 2022 08:00 am ET
Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin
This Fourth Patent for AR101/Enzastaurin Strengthens and Broadens the Intellectual Property Portfolio Surrounding the Treatment of Inherited Vascular Disorders Including Vascular Ehlers-Danlos Syndrome (VEDS).
Aug 24, 2022 08:00 am ET
Aytu BioPharma to Participate in September 2022 Investor Conferences
ENGLEWOOD, CO / ACCESSWIRE / August 24, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, today announced that Aytu's management team will virtually present at, and participate in, the upcoming H.C. Wainwright 24th Annual Global Investment Conference and Lytham Partners Fall 2022 Investor Conference.
Aug 16, 2022 08:00 am ET
Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
First Issued U.S. Patent Covers Methods of Treating a Broad Range of Inherited Aortic Aneurism and Related Conditions Including Vascular Ehlers-Danlos Syndrome
Aug 15, 2022 04:01 pm ET
Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering
ENGLEWOOD, CO / ACCESSWIRE / August 15, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of its previously announced underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 1,750,000 shares of its common stock, and (ii) accompanying warrants (the "Common Warrants") to purchase 23,255,814 shares of its
Aug 09, 2022 09:15 am ET
Aytu BioPharma Announces Pricing of Public Offering
ENGLEWOOD, CO / ACCESSWIRE / August 9, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 1,750,000 shares of its common stock, and (ii) accompanying warrants (the "Common Warrants") to purchase 23,255,814 shares of its common stock (the &qu
Aug 08, 2022 04:01 pm ET
Aytu BioPharma Announces Launch of Public Offering
ENGLEWOOD, CO / ACCESSWIRE / August 8, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the launch of an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, and accompanying warrants to purchase its common stock (the "Offering"). All of the securities in the Offering will be sold by Aytu. The Offe
Jul 26, 2022 08:00 am ET
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference
ENGLEWOOD, CO / ACCESSWIRE / July 26, 2022 / Aytu BioPharma, Inc. (the "Company") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that Chief Executive Officer Josh Disbrow and Chief Financial Officer Mark Oki will participate in the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022 at the InterContinental Hotel in Boston, MA.
Jul 20, 2022 08:00 am ET
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
ENGLEWOOD, CO / ACCESSWIRE / July 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the initiation of the global Phase 3 PREVEnt (Prevention of Ruptures with Enzastaurin for Vascular Ehlers-Danlos Syndrome) clinical trial of enzastaurin (AR101) for the treatment of patients with COL3A1-positive Vascular Ehlers-Danlos Syndrome (VEDS). VEDS is a rare genetic disorder typically diagnosed in childhood and characterized by arterial aneurysm, dissect
Jun 29, 2022 08:00 am ET
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors
ENGLEWOOD, CO / ACCESSWIRE / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment of Vivian Liu to the company's board of directors, effective July 1, 2022. Ms. Liu will serve as an independent director and as a member of the Nominating & Corporate Governance Committee.
Jun 13, 2022 08:00 am ET
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference
ENGLEWOOD, CO / ACCESSWIRE / June 13, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the company will be participating in the Lytham Partners Summer 2022 Investor Conference taking place virtually on June 21-22, 2022.
May 16, 2022 04:02 pm ET
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities
Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company History
Apr 25, 2022 08:00 am ET
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology
Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Delaying Time to Development of Ventilator-Associated Pneumonia
Apr 19, 2022 09:31 am ET
Thinking about buying stock in Aytu Biopharma, Casa Systems, Highpeak Energy, MRC Global, or DocGo?
NEW YORK, April 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AYTU, CASA, HPK, MRC, and DCGO.
Apr 19, 2022 08:00 am ET
Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome
ENGLEWOOD, CO / ACCESSWIRE / April 19, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AR101 (enzastaurin), a protein kinase C (PKC) β inhibitor, for the treatment of patients with Vascular Ehlers-Danlos Syndrome (VEDS).
Mar 23, 2022 08:00 am ET
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)
ENGLEWOOD, CO / ACCESSWIRE / March 23, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that its newly issued US patent No. 11,166,947 for Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablet is now listed in the U.S. Food and Drug Administration (FDA) publication, "Approved Drug Products with Therapeutic Equivalence Evaluations", commonly known as the "Orange Book." The Cotempla XR-ODT patent covers methods of use for the effect
Mar 22, 2022 08:00 am ET
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
ENGLEWOOD, CO / ACCESSWIRE / March 22, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that management will participate in a panel discussion titled, "Managing Clinical Trials for Rare Diseases During & After COVID-19," during the Cantor Fitzgerald Virtual Rare Orphan Disease Summit on Tuesday, March 29, 2022 at 11:00 a.m. ET.
Mar 08, 2022 08:00 am ET
Aytu BioPharma to Participate in the 34th Annual Roth Conference
ENGLEWOOD, CO / ACCESSWIRE / March 8, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that Mark Oki, chief financial officer, and Greg Pyszczymuka, chief commercial officer of Aytu BioPharma, will participate in a fireside chat during the 34th Annual Roth Conference on Tuesday, March 15, 2022 at 2:00 p.m. PT. Management will also host one-on-one meetings with investors during the conference. The conference will be held in Dana Point, California from March 13-15, 2022.
Mar 07, 2022 04:05 pm ET
Aytu BioPharma Announces Closing of $7.6 Million Registered Offering
ENGLEWOOD, CO / ACCESSWIRE / March 7, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of its previously announced underwritten offering of 3,030,000 shares of its common stock, pre-funded warrants to purchase up to 3,030,000 shares of its common stock, and common warrants to purchase up to 6,666,000 shares of its common stock (the "Offering") resulting in gross proceeds of $7.6 million, assuming none of the accompanying common warrants issued in the Offering
Mar 02, 2022 08:00 pm ET
Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering
ENGLEWOOD, CO / ACCESSWIRE / March 2, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the placement to a healthcare-dedicated institutional investor in an underwritten offering of 3,030,000 shares of its common stock, pre-funded warrants to purchase up to 3,030,000 shares of its common stock, and common warrants to purchase up to 6,666,000 shares of its common stock (the "Offering"). The shares of common stock and the pre-funded warrants are each being sold in combinatio
Mar 02, 2022 08:00 am ET
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome
ENGLEWOOD, CO / ACCESSWIRE / March 2, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the European Commission granted orphan designation to AR101 (enzastaurin), a PKCβ inhibitor, for the treatment of Ehlers-Danlos Syndrome (EDS), a group of rare inherited connective tissue disorders that includes the severe subtype vascular EDS (VEDS). This designation is based on a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA CO
Feb 14, 2022 04:05 pm ET
Jan 31, 2022 08:00 am ET
Aytu BioPharma Completes $15 Million Debt Refinancing
ENGLEWOOD, CO / ACCESSWIRE / January 31, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that it has entered into an agreement with the Avenue Venture Opportunities Fund, L.P., an affiliate of Avenue Capital Group, to refinance the company's existing senior secured loan facility.
Jan 04, 2022 08:00 am ET
Aytu BioPharma Appoints Mark Oki as Chief Financial Officer
ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that Mark Oki will join Aytu as the company's chief financial officer effective January 17, 2022. Mr. Oki will serve as a member of Aytu's executive committee and will report to Josh Disbrow, chief executive officer. Mr. Oki will provide leadership and oversight of the company's financial operations and planning, accounting, information technology and select other functions.
Jan 03, 2022 08:00 am ET
Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference
ENGLEWOOD, CO / ACCESSWIRE / January 3, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that Josh Disbrow, chief executive officer of Aytu, will present a pre-recorded company presentation at the H.C. Wainwright BioConnect Conference, which will become available for on-demand viewing on Monday, January 10, 2022 at 7:00 a.m. ET.
Dec 14, 2021 08:30 am ET
Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome
SAN DIEGO, Dec. 14, 2021 /PRNewswire/ -- Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, today announced its partner Aytu BioPharma (Nasdaq: AYTU), has received FDA clearance for its IND application for enzastaurin and also Orphan Drug Designation (ODD) for enzastaurin for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS).
Dec 08, 2021 08:00 am ET
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome
ENGLEWOOD, CO / ACCESSWIRE / December 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to AR101 (enzastaurin) for the treatment of Ehlers-Danlos Syndrome. Treatment of vascular Ehlers-Danlos Syndrome (VEDS) is within the scope of this orphan drug designation. The company plans to launch a single pivotal trial, the PREVEnt Trial, of AR101 in patients with VEDS in the f
Nov 23, 2021 08:00 am ET
Aytu BioPharma Announces Issuance of First U.S. Patent Supporting Healight Ultraviolet-A Respiratory Catheter
ENGLEWOOD, CO / ACCESSWIRE / November 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced that today the United States Patent and Trademark Office (USPTO) has issued a U.S. patent for the Healight™ ultraviolet-A light-based respiratory catheter. U.S. Patent Number 11,179,575, titled "Internal Ultraviolet Therapy," is the first issued patent protecting the Healight investigational device and covers methods of treating a patient for an infectiou
Nov 17, 2021 08:00 am ET
Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 50(TM)
ENGLEWOOD, CO / ACCESSWIRE / November 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced it ranked 178 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 27th
Nov 15, 2021 04:00 pm ET
Aytu BioPharma Reports First Quarter 2022 Financial Results
Quarterly net revenue increased 62% to $21.9 million
Nov 08, 2021 08:05 am ET
Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021
ENGLEWOOD, CO / ACCESSWIRE / November 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on November 15, 2021, at 4:30 p.m. ET. The Company will review accomplishments from the first quarter fiscal 2022 and provide an overview of its business and growth strategy.
Oct 04, 2021 04:49 pm ET
ALERT: Rowley Law PLLC is Investigating Potential Breaches of Fiduciary Duty by the Aytu BioPharma, Inc. Board of Directors
NEW YORK, Oct. 4, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating a potential breach of fiduciary duty claim involving the board of directors of Aytu BioPharma, Inc. (NASDAQ: AYTU).
Sep 30, 2021 08:01 am ET
CORRECTION: Aytu BioPharma to Present at Upcoming September Investor Conferences
(This release corrects the previous one that was issued on September 7, 2021 to reflect the time of the Cantor Presentation being changed to 2:40 pm EST)
Sep 27, 2021 04:01 pm ET
Aytu BioPharma Reports Fourth Quarter and Full-Year Fiscal 2021 Financial Results
Quarterly net revenue increased 74% sequentially to $23.5M; 138% year-over-year to $65.6M
Sep 23, 2021 08:00 am ET
Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021
ENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on September 27, 2021, at 4:30 p.m. ET. The Company will review accomplishments from the fourth quarter and fiscal year 2021 and provide an overview of its business and growth strategy.
Sep 09, 2021 08:00 am ET
Aytu BioPharma Announces Formation of New Scientific Advisory Board to Support Development of AR101 for Vascular Ehlers-Danlos Syndrome
Chaired by Dr. Hal Dietz and joined initially by Dr. Xavier Jeunemaitre, Dr. Shaine Morris, Dr. Bart Loeys, and Dr. Peter Byers with additional advisors to be added
Sep 08, 2021 07:00 am ET
SHAREHOLDER ALERT: Morris Kandinov Investigating ODT, AYTU, EAR, and CORT; Shareholders are Encouraged to Contact the Firm
National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Odonate Therapeutics, Inc., Aytu Biopharma, Inc., Eargo, Inc., and Corcept Therapeutics, Inc.   If you are a current owner of shares of any of...
Jul 27, 2021 08:05 am ET
Aytu BioPharma Announces Publication of Data Demonstrating Ultraviolet-A Light Reduces Cellular Cytokine Release from Human Endotracheal Cells Infected with Coronavirus
ENGLEWOOD, CO / ACCESSWIRE / July 27, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that data from a laboratory study evaluating the ultraviolet A light used in the Healight™ endotracheal catheter technology was published in the peer reviewed journal Photodiagnosis and Photodynamics Therapy.
Jun 28, 2021 08:50 am ET
Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study
Results Indicate That Endotracheal UVA Light Catheter Therapy is Associated with Significant Reduction in SARS-CoV-2 Viral Load and Improvement in Clinical Outcomes in Mechanically Ventilated COVID-19 Patients
Jun 21, 2021 08:30 am ET
Thinking about buying stock in Anavex Life Sciences, Globalstar, Rapt Therapeutics, Aytu Biopharma, or Evofem Biosciences?
NEW YORK, June 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVXL, GSAT, RAPT, AYTU, and EVFM.
May 25, 2021 08:01 am ET
Aytu BioPharma to Present at Upcoming June Investor Conferences
ENGLEWOOD, CO / ACCESSWIRE / May 25, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that Josh Disbrow, Chairman and Chief Executive Officer, will present at two upcoming investor conferences in June:
May 17, 2021 04:01 pm ET
Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights
- Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company -
May 12, 2021 10:50 am ET
Aytu BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial Anti-Viral Signaling Protein Within Cells
ENGLEWOOD, CO / ACCESSWIRE / May 12, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that in vitro data related to the ultraviolet (UV) A light used in the Healight™ UVA endotracheal catheter technology was published in BioRxiv, an online archive for health science manuscripts that are not yet peer reviewed.
May 10, 2021 04:01 pm ET
Aytu BioPharma to Report Third Quarter Fiscal 2021 Results on May 17, 2021
ENGLEWOOD, CO / ACCESSWIRE / May 10, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on Monday, May 17, 2021, at 4:30 p.m. ET to report its financial results for the fiscal third quarter ended March 31, 2021 and review recent accomplishments.
Apr 12, 2021 08:00 am ET
Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics
ENGLEWOOD, CO / ACCESSWIRE / April 12, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the acquisition of a global license to AR101 (enzastaurin), a pivotal study-ready therapeutic candidate initially targeting the treatment of vascular Ehlers-Danlos Syndrome (vEDS) from Rumpus Therapeutics (Rumpus), a privately-held biopharmaceutical company focused on the treatment of pediatric onset rare and orphan diseases. vEDS is a rare genetic disorder typically diagnosed
Apr 05, 2021 08:00 am ET
Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer
ENGLEWOOD, CO / ACCESSWIRE / April 5, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the appointment of Richard Eisenstadt as Chief Financial Officer. Mr. Eisenstadt is an accomplished pharmaceutical industry executive with more than 20 years of experience in leading finance and accounting operations, supporting clinical development and commercialization, and raising capital within the life sciences sector.
Apr 01, 2021 07:30 am ET
Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma
Strategic Transaction Provides $7.5M in Non-Dilutive Capital and Enables Pediatric and ADHD Product Focus Following the Recently Closed Merger with Neos Therapeutics
Mar 22, 2021 06:00 am ET
Aytu BioScience Announces Close of Merger with Neos Therapeutics
ENGLEWOOD, CO / ACCESSWIRE / March 22, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the closing of its merger with Neos Therapeutics (previously trading on Nasdaq under "NEOS"). The combined, publicly traded company will focus on maximizing its commercial portfolio of prescription therapeutics and consumer health products and building a complementary novel therapeutic development pipeline that will address significant unmet needs. Effectiv
Mar 08, 2021 04:01 pm ET
Aytu BioScience Announces Positive Clinical Results from Healight(TM) Pilot Study in SARS-CoV-2 Patients
Data indicate endotracheal UVA light catheter therapy reduces SARS-CoV-2 viral load and improves clinical outcomes in mechanically ventilated SARS-CoV-2 patients
Feb 24, 2021 08:00 am ET
Aytu BioScience to Present at Upcoming March Investor Conferences
ENGLEWOOD, CO / ACCESSWIRE / February 24, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Josh Disbrow, Chairman and Chief Executive Officer will present at three upcoming investor conferences in March:
Feb 11, 2021 04:01 pm ET
Aytu BioScience Announces Record Fiscal Q2 2021 Net Revenue of $15.1 Million, an Increase of 377% Year-Over-Year
Announced definitive merger agreement with Neos Therapeutics, creating a combined $100 million revenue specialty pharmaceutical company
Feb 10, 2021 08:00 am ET
Feb 10, 2021 08:00 am ET
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021
Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial-stage pharmaceutical company...
Feb 04, 2021 08:00 am ET
Dec 28, 2020 08:05 am ET
Aytu BioScience Announces Completion of Healight(TM) Safety Study in Critically Ill COVID-19 Patients
First Safety Study Utilizing Ultraviolet A Light Catheter as a Prospective Anti-Infective in Critically Ill, Intubated SARS-Cov-2 Patients
Dec 16, 2020 08:20 pm ET
NEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Neos Therapeutics, Inc. - NEOS
NEW ORLEANS, Dec. 16, 2020 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Neos Therapeutics, Inc. (NasdaqGS: NEOS) to Aytu BioScience, Inc. (NasdaqGS: AYTU).  Under the terms of the proposed transaction, shareholders of Neos will receive only 0.1088 shares of Aytu for each share of Neos that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Dec 15, 2020 12:00 pm ET
Aytu BioScience Announces Closing of $28.75 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
ENGLEWOOD, CO / ACCESSWIRE / December 15, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), ("Aytu" or "the Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today the closing of its previously announced underwritten public offering of 4,791,667 shares of common stock of the Company, which includes the full exercise of the underwriter's option to purchase an additional 625,000 shares of common stock, at a price to the public of $6.00 per share.
Dec 14, 2020 08:01 am ET
Aytu BioScience to Present at the LD Micro Virtual Investor Conference on Tuesday, December 15 at 2:20pm ET
ENGLEWOOD, CO / ACCESSWIRE / December 14, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that management will present at the LD Micro Virtual Investor Conference on Tuesday, December 15 at 2:20pm ET.
Dec 11, 2020 11:41 am ET
NEOS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of NEOS and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Neos Therapeutics, Inc. (NASDAQ: NEOS) breached their fiduciary duties or violated the federal...
Dec 11, 2020 10:38 am ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Neos Therapeutics, Inc. Merger
Rigrodsky & Long, P.A. announces that it is investigating Neos Therapeutics, Inc. (“Neos”) (NASDAQ GS: NEOS) regarding possible breaches of fiduciary duties and other violations of law related to Neos’ agreement to be acquired by Aytu BioScience,...
Dec 10, 2020 11:10 pm ET
Aytu BioScience Increases Previously Announced Bought Deal Offering to $25.0 Million
ENGLEWOOD, CO / ACCESSWIRE / December 10, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 4,166,667 shares of common stock of the Company, at a price to the public of $6.00 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 15, 2020, su
Dec 10, 2020 06:35 pm ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Neos Therapeutics, Inc.
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Neos Therapeutics, Inc. (NASDAQ: NEOS) and its board of directors concerning the proposed acquisition of the company by Aytu BioScience, Inc. (NASDAQ: AYTU). Stockholders will receive 0.1088 shares of Aytu BioScience common stock for each share of Neos Therapeutics stock that they hold. The transaction is valued at approximately $44.9 million and is expected to close by the second quarter of 2021.
Dec 10, 2020 05:35 pm ET
Aytu BioScience Announces $10.0 Million Bought Deal Offering
ENGLEWOOD, CO / ACCESSWIRE / December 10, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,666,667 shares of common stock of the Company, at a price to the public of $6.00 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December
Dec 10, 2020 03:52 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Neos Therapeutics, Inc.
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neos Therapeutics, Inc. ("NEOS" or the "Company") (NASDAQ: NEOS) in connection with the proposed acquisition of the Company by Aytu BioScience, Inc. ("Aytu") (NASDAQ: AYTU).  Under the terms of the merger agreement, NEOS shareholders will be entitled to receive 0.1088 shares of Aytu common stock for each NEOS share that they own, representing implied per-share merger consideration of a mere $0.74 based upon Aytu's December 9, 2020
Dec 10, 2020 08:00 am ET
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue¹ Specialty Pharmaceutical Company
Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial-stage pharmaceutical company...
Dec 10, 2020 06:01 am ET
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company
ENGLEWOOD, CO and GRAND PRAIRIE, TX / ACCESSWIRE / December 10, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that they have entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.
Nov 12, 2020 04:01 pm ET
Nov 11, 2020 08:00 am ET
Aytu BioScience to Present at the Jefferies 2020 Virtual London Healthcare Conference Wednesday, November 18 at 1:45pm ET
ENGLEWOOD, CO / ACCESSWIRE / November 11, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that management will present a corporate overview at the Jefferies 2020 Virtual London Healthcare Conference on Wednesday, November 18 at 1:45pm ET / 6:45pm GMT.
Oct 06, 2020 04:02 pm ET
Aytu BioScience Announces Fiscal Q4 2020 Net Revenue of $14.9 Million, an Increase of 82% Sequentially, and 766% Year-Over-Year
Company's highest revenue quarter to date is more than 2X its entire fiscal 2019 revenue
Sep 23, 2020 06:00 pm ET
Aytu BioScience to Reschedule Fourth Quarter and FY 2020 Conference Call
ENGLEWOOD, CO / ACCESSWIRE / September 23, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that it will reschedule its fourth quarter and FY 2020 conference call, previously scheduled for Thursday, September 24 at 4:30pm ET.
Sep 08, 2020 08:00 am ET
Aytu BioScience Announces Global Agreement to Distribute Pinnacle IVD Corporation's 15-Minute COVID-19 Antigen Test
Pinnacle Plans to Scale U.S. Manufacturing Capacity to 25 Million Tests Per Month
Aug 19, 2020 08:00 am ET
Aytu BioScience Announces Launch of Nationwide Mobile COVID-19 Testing Initiative
Aytu BioScience COVID-19 IgG/IgM Rapid Test Distribution Partner Apollo Med Innovations Initiates Nationwide Mobile Testing Partnership with Olympus Health and Performance
Aug 17, 2020 08:00 am ET
Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for Use in COVID-19 Clinical Study
Delivery of Investigational Endotracheal Ultraviolet-A Light Catheter Devices Enables Near-Term Initiation of Planned Clinical Studies in Severely Ill COVID-19 Patients
Aug 05, 2020 09:00 am ET
LD Micro Announces Preliminary List of Presenters for the LD 500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Jul 30, 2020 08:00 am ET
Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration
Aytu BioScience's Sublicensee SUDA Pharmaceuticals Secures TGA Approval, Enabling Near-Term Commercialization of ZolpiMist
Jul 27, 2020 08:00 am ET
COVID-19 IgG/IgM Rapid Test Cassette Distributed by Aytu BioScience Featured in Business Insider Article
Article Reports Results from Independent Study Demonstrating Test's 100% Sensitivity and Specificity for IgM Antibodies and 96.7% and 97.5% Sensitivity and Specificity, Respectively, for IgG Antibodies
Jul 20, 2020 07:30 am ET
Aytu BioScience Announces Expansion of NATESTO(R) U.S. Commercial Team
Commercial Partner Acerus Pharmaceuticals Launches Specialty Sales Team Calling on Urologists and Endocrinologists in the United States
Jul 10, 2020 09:31 am ET
Thinking about buying stock in Unum Therapeutics, Nokia, Amneal Pharmaceuticals, Aytu Bioscience, or Niu Technologies?
NEW YORK, July 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UMRX, NOK, AMRX, AYTU, and NIU.
Jul 10, 2020 08:00 am ET
Aytu BioScience Announces Distribution Partnership with Apollo Med Innovations to Expand Distribution of COVID-19 IgG/IgM Rapid Test in United States
Apollo Med Innovations Introduces Novel Research-Based Testing Approach to Offer COVID-19 Antibody Testing to Nationwide Network of Over 1,000 Medical Clinics and Recently Launched Mobile Testing Platform
Jun 26, 2020 09:31 am ET
Thinking about buying stock in Citius Pharmaceuticals, Aytu Bioscience, Applied DNA Sciences, Royal Caribbean Cruises, or American Airlines?
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, AYTU, APDN, RCL, and AAL.
Jun 09, 2020 08:00 am ET
Aytu BioScience Announces Results from a National Cancer Institute Evaluation of the Company’s Licensed COVID-19 IgG/IgM Rapid Test
National Cancer Institute's (NCI) analysis of COVID-19 IgG/IgM Rapid Test Cassette Reported 100% Combined Sensitivity, and 97.5% Combined Specificity for the Lateral Flow Immunoassay
Jun 08, 2020 08:00 am ET
Aytu BioScience Set to Join Russell 3000(R) Index
ENGLEWOOD, CO / ACCESSWIRE / June 8, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant medical needs, is set to join the Russell 3000® Index at the conclusion of the 2020 Russell indexes annual reconstitution. The Russell index changes become effective after the close of the US markets on June 26, 2020 according to a preliminary list of additions posted June 5. The Company is already included in the Russell Microcap Index.
Jun 03, 2020 08:00 am ET
Aytu BioScience Announces Significant Improvement in Natesto(R) Patient Access in the United States
Natesto now covered as a Preferred Brand by leading national pharmacy benefits manager
Jun 01, 2020 04:01 pm ET
Aytu BioScience Announces $15 Million Debt Retirement
Company Retires $15M Obligation Assumed with Previously Announced Cerecor Commercial Portfolio Asset Purchase
Jun 01, 2020 08:00 am ET
Aytu BioScience Announces Emergency Use Authorization of COVID-19 IgG/IgM Rapid Test
Fourth FDA Emergency Use Authorization of a COVID-19 IgG/IgM Lateral Flow Rapid Test
May 14, 2020 04:01 pm ET
Aytu BioScience Reports Third Quarter Fiscal 2020 Financial Results
Company Reports Revenue for the Three Months Ended March 31, 2020 of $8.2M, Up 243% Year-over-Year
May 14, 2020 09:31 am ET
Thinking about buying stock in Aurora Cannabis, Co-Diagnostics, NovaBay Pharmaceuticals, Aytu Bioscience, or American Airlines Group?
NEW YORK, May 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, CODX, NBY, AYTU, and AAL.
May 11, 2020 09:31 am ET
Thinking about buying stock in AMC Entertainment, Carnival Corp, OraSure Technologies, Inovio Pharmaceuticals, or Aytu Bioscience?
NEW YORK, May 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, CCL, OSUR, INO, and AYTU.
May 07, 2020 08:00 am ET
Aytu BioScience to Report Fiscal Q3 FY 2020 Results and Business Update
ENGLEWOOD, CO / ACCESSWIRE / May 7, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational results for the quarter ended March 31, 2020 on May 14, 2020, at 4:30 p.m. ET. The Company will review accomplishments from the quarter and provide an overview of its business and growth strategy.
May 05, 2020 05:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aytu BioSciences, Inc. - AYTU
Pomerantz LLP is investigating claims on behalf of investors of Aytu BioSciences, Inc. (“Aytu” or the “Company”) (NASDAQ: AYTU).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Apr 30, 2020 11:45 am ET
Aytu BioScience Announces China Export Clearance of Company's COVID-19 IgG/IgM Rapid Test
500,000 Rapid Tests Cleared for Shipment to Company's Warehouse
Apr 28, 2020 09:31 am ET
Thinking about buying stock in Aytu Bioscience, SmileDirectClub, Ocular Therapeutix, Six Flags Entertainment, or MGM Resorts?
NEW YORK, April 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AYTU, SDC, OCUL, SIX, and MGM.
Apr 27, 2020 09:55 am ET
Aytu BioScience Signs Development Agreement with Sterling Medical Devices to Advance the Development of Healight as a Potential Coronavirus Treatment
Company has Partnered with Sterling Medical to Finalize the Development of Cedars-Sinai-Developed 'Healight' Medical Device for Use in Patients with Coronavirus
Apr 24, 2020 08:00 am ET
Aytu BioScience Announces Results from Annual Stockholders Meeting
Company's Board of Directors Elects Not to Effect a Reverse Stock Split
Apr 23, 2020 09:31 am ET
Thinking about buying stock in Aytu Bioscience, Ford, Penn National Gaming, Transocean, or Taronis Technologies?
NEW YORK, April 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AYTU, F, PENN, RIG, and TRNX.
Apr 23, 2020 08:00 am ET
Aytu BioScience Announces Exclusive Distribution Agreement for COVID-19 IgG/IgM Rapid Test with Singapore-Based Biolidics Limited
ENGLEWOOD, CO / ACCESSWIRE / April 23, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced the signing of a definitive agreement (the "Agreement") with Singapore-based Biolidics, Limited (SGX: 8YY; "Biolidics") to exclusively distribute Biolidics' COVID-19 IgG/IgM Rapid Test in the United States.
Apr 21, 2020 08:23 pm ET
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Aytu BioScience Inc. Investors (AYTU)
The Law Offices of Frank R. Cruz announces an investigation on behalf of Aytu BioScience Inc. ("Aytu" or the Company") (NASDAQ: AYTU) investors concerning the Company and its officers’ possible violations of federal securities laws.
Apr 21, 2020 06:30 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Aytu BioScience, Inc. (AYTU) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf Aytu BioScience, Inc. ("Aytu" or the Company") (NASDAQ:
Apr 21, 2020 04:42 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Aytu BioScience, Inc. (AYTU) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Aytu BioScience, Inc. ("Aytu" or the Company") (NASDAQ: AYTU) investors concerning the Company and its officers’ possible violations of federal securities laws.
Apr 21, 2020 08:00 am ET
Aytu BioScience Announces Publication of Results from Natesto Spermatogenesis Study in Journal of Urology
Nasally-Administered Natesto Testosterone Replacement Therapy Increases Serum Testosterone, Improves Hypogonadal Symptoms While Simultaneously Preserving Semen Parameters and Gonadotropin Hormones
Apr 20, 2020 03:02 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aytu BioSciences, Inc.  - AYTU
Pomerantz LLP is investigating claims on behalf of investors of Aytu BioSciences, Inc. (“Aytu” or the “Company”) (NASDAQ: AYTU)   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Apr 20, 2020 10:00 am ET
AYTU INVESTIGATION: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Investigation of Aytu BioSciences, Inc.
NEW YORK, April 20, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aytu BioSciences, Inc. ("Aytu" or "the Company") (NASDAQ: AYTU). Investors who purchased Aytu securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/aytu.        
Apr 20, 2020 08:00 am ET
Aytu BioScience Signs Exclusive Global License with Cedars-Sinai for Potential Coronavirus Treatment
Cedars-Sinai-Developed ‘Healight' Medical Device Platform Technology Being Studied as a Potential First-in-Class COVID-19 Treatment
Apr 17, 2020 09:37 am ET
Aytu BioScience Investigated for Possible Securities Laws Violations; Investors Who Lost Money Should Contact Block & Leviton
Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, is investigating Aytu BioScience, Inc. (NASDAQ: AYTU) and certain of its officers for potential securities fraud.  Investors who purchased Aytu shares should contact...
Apr 17, 2020 08:25 am ET
Aytu BioScience Confirms Export and Incoming Delivery of COVID-19 IgG/IgM Rapid Tests
Chinese Officials Confirm China Won't Restrict Exports of Medical Products Needed to Fight Coronavirus
Apr 16, 2020 08:00 am ET
Aytu BioScience Announces Positive Results from an Independently Conducted Clinical Study of the Company's Licensed COVID-19 IgG/IgM Point-of-Care Rapid Test
Independent clinical study demonstrates test accuracy of 98.0% and 94.1% for IgG and IgM, respectively, when using PCR-positive cases as true positives
Apr 15, 2020 09:31 am ET
Thinking about buying stock in Aytu Bioscience, Boeing, Canopy Growth Corp, Moderna, or Rite Aid?
NEW YORK, April 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AYTU, BA, CGC, MRNA, and RAD.
Apr 15, 2020 08:00 am ET
Apr 13, 2020 08:00 am ET
Aytu BioScience Consumer Health Subsidiary Launches Regoxidine(R), an FDA Approved Hair Regrowth Treatment Foam that Contains 5% Minoxidil and Targets Over 11 Million U.S. Consumers Who Purchased Hair
ENGLEWOOD, CO / ACCESSWIRE / April 13, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today the launch of Regoxidine®, an over-the-counter foam formulation of minoxidil available for use by both men and women. Regoxidine® is indicated for hair treatment and regrowth and is available through the company's recently acquired, wholly-owned subsidiary Innovus Pharmaceuticals. Regoxidine® is a branded alternative to hair regrowth treatment Rogaine®
Apr 09, 2020 08:00 am ET
Aytu BioScience Announces Updated Annual Shareholder Meeting Date and Virtual Room Access
ENGLEWOOD, CO / ACCESSWIRE / April 9, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced that, due to Colorado's "shelter in place" order related to the Coronavirus Disease ("COVID-19") crisis, the Company has rescheduled the upcoming annual meeting of the stockholders, originally scheduled for March 31, 2020, to April 23, 2020 at 11:00 AM, Mountain Time. Further instructions on how to attend, participate in an
Apr 08, 2020 08:00 am ET
Aytu BioScience Announces Exclusive ZolpiMist(TM) License to Commercialize Aytu's Oral Spray Sleep Aid in South Korea
Aytu BioScience Licensee SUDA Pharmaceuticals Expands ZolpiMist Global Footprint Through Exclusive Licensing Agreement with Mitsubishi Tanabe Pharma Corporation
Apr 07, 2020 08:00 am ET
Aytu BioScience Receives $23.0 Million from Warrant Exercises
Cash and Cash Equivalents of Approximately $62.5 on March 31, 2020
Apr 03, 2020 09:31 am ET
Thinking about buying stock in Aytu Bioscience, Citigroup, Chewy, Fate Therapeutics, or General Electric?
NEW YORK, April 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AYTU, C, CHWY, FATE, and GE.
Apr 03, 2020 09:15 am ET
XpresSpa Pursues Novel Coronavirus (COVID-19) Screening and Testing at U.S. Airports
XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), today provided an update on recent discussions with local airport authorities and healthcare partners so that it may begin providing screening and testing for novel coronavirus...
Apr 03, 2020 08:00 am ET
Apr 01, 2020 09:31 am ET
Thinking about buying stock in Advanced Micro Devices, Aytu Bioscience, Inseego, Moderna, or SuperCom?
NEW YORK, April 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, AYTU, INSG, MRNA, and SPCB.
Apr 01, 2020 08:00 am ET
Aytu BioScience Announces Receipt of Initial Shipment of 100,000 COVID-19 IgG/IgM Point-of-Care Rapid Tests; Additional 500,000 Tests on Order
Initial Shipment of 2-10 Minute COVID-19 Rapid Tests Received at Company's Englewood, Colorado Facility
Mar 30, 2020 08:00 am ET
AYTU Announces Delay of Annual Meeting of Stockholders Due to Colorado's "Shelter in Place" Order Related to the COVID-19 Crisis
ENGLEWOOD, CO / ACCESSWIRE / March 30, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that its annual meeting of stockholders originally scheduled to be held on March 31, 2020 at 10:00 a.m. MST will be delayed to a later date to be determined by its Board of Directors (the "Annual Meeting"). The Company hopes to have the Annual Meeting by April 25, 2020 so that the record date for determining shareholders entitled
Mar 27, 2020 09:31 am ET
Thinking about buying stock in Aytu Bioscience, GameStop, Translate Bio, Tilray, or T2 Biosystems?
NEW YORK, March 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AYTU, GME, TBIO, TLRY, and TTOO.
Mar 25, 2020 08:00 am ET
Aytu BioScience Regains Compliance with NASDAQ Minimum Bid Price Requirement
ENGLEWOOD, CO / ACCESSWIRE / March 25, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced that it received notice from The Nasdaq Stock Market, LLC ("Nasdaq") on March 24, 2020 indicating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule") for continued listing on The Nasdaq Capital Market. Accordingly, the Company has regained complianc
Mar 23, 2020 08:00 am ET
Mar 19, 2020 12:40 pm ET
Aytu Announces $20 Million Registered Direct Offering Priced At-the-Market
ENGLEWOOD, CO / ACCESSWIRE / March 19, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of an aggregate 12,539,187 shares of Aytu's common stock and warrants to purchase an aggregate of up to 12,539,187 shares of common stock, at a combined purchase price of $1.595 per share and associated warrant, in a registered direct offering
Mar 19, 2020 08:00 am ET
Aytu BioScience Expands Its Distribution Rights for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test to Canada and Mexico
Company Expects to Seek Regulatory Clearance Under Health Canada and COFEPRIS Expedited Clearance Procedures
Mar 17, 2020 11:55 am ET
Aytu BioScience Announces Acceleration of U.S. Availability of COVID-19 IgG/IgM Rapid Test Based on Updated FDA Policy
Updated FDA Policy Likely Enables Near-Term Availability of COVID-19 Test in the U.S.
Mar 16, 2020 12:00 pm ET
Aytu BioScience's Coronavirus Rapid Test Featured on NBC and Fox News (VIDEOS): ''Englewood Company Says It Can Get COVID-19 Test Results in 2-10 Minutes"; "2-Minute COVID-19 Test Results? Denver-Area
ENGLEWOOD, CO / ACCESSWIRE / March 16, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today it was featured on a FOX segment titled: "Englewood company says it can get COVID-19 test results in 2-10 minutes," reported on by affiliated television station in Denver, Colorado, KDVR; and on an NBC segment titled "2-minute COVID-19 test results? Denver-area company wants to deliver that promise," reported on by affiliated television station in Denver,
Mar 13, 2020 08:00 am ET
Aytu BioScience Establishes COVID-19 IgG/IgM Rapid Test Product Inquiry Procedure for Healthcare Professionals and Institutions
Healthcare professionals, institutions, and other interested parties with questions about the Company's recently licensed COVID-19 IgG/IgM Rapid Test are asked to send email inquiries to [email protected]
Mar 12, 2020 08:00 am ET
Aytu Announces $20 Million Registered Direct Offering Priced At-the-Market
ENGLEWOOD, CO / ACCESSWIRE / March 12, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of an aggregate 16,000,000 shares of Aytu's common stock and warrants to purchase an aggregate of up to 16,000,000 shares of common stock, at a combined purchase price of $1.25 per share and associated warrant, in a registered direct offering p
Mar 11, 2020 08:00 am ET
Aytu Announces $9.0 Million Registered Direct Offering Priced At-the-Market
ENGLEWOOD, CO / ACCESSWIRE / March 11, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor for the purchase and sale of 7,826,087 shares of Aytu's common stock (or common stock equivalent), at a purchase price of $1.15 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or
Mar 10, 2020 08:05 am ET
Aytu BioScience Secures Exclusive U.S. Distribution Agreement for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test
Company Expects to Pursue Commercial Use Under FDA's Emergency Use Authorization
Feb 18, 2020 09:00 am ET
Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals
Aytu BioScience Enters Consumer Healthcare Market with a Portfolio of Over 35 Products that Generated $24M in Revenue During Past Four Quarters
Feb 13, 2020 04:10 pm ET
Aytu Reports Q2 Revenue of $3.2M, Up 77% Year-over-Year and 121% Sequentially
ENGLEWOOD, CO / ACCESSWIRE / February 13, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant medical needs, today will provide an overview of its business, including the company's operational and financial results for its fiscal second quarter 2020 that ended December 31, 2019. The company will host a live conference call and webcast today at 4:30 p.m. ET. Conference call details are provided at the end of this press release.
Feb 06, 2020 09:00 am ET
Aytu BioScience to Report Fiscal Q2 FY 2020 Results and Business Update
ENGLEWOOD, CO / ACCESSWIRE / February 6, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that the company will present its operational results for the quarter ended December 31, 2019 on February 13, 2020, at 4:30 p.m. ET. The company will review accomplishments from the quarter and provide an overview of its business and growth strategy.
Feb 05, 2020 09:00 am ET
Aytu BioScience Announces Acceptance of Results of Two Natesto Clinical Studies for Presentation at American Urological Association Annual Scientific Program
ENGLEWOOD, CO / ACCESSWIRE / February 5, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced the acceptance of scientific abstracts reporting the findings from two Natesto® clinical studies for presentation at the American Urological Association's AUA2020 Scientific Program. The AUA2020 meeting will be held May 15th - 18th in Washington, DC.
Jan 28, 2020 09:00 am ET
Aytu BioScience Announces Acceptance of Natesto Spermatogenesis Study Results for Presentation at ENDO 2020
ENGLEWOOD, CO / ACCESSWIRE / January 28, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs today announced the acceptance of a scientific abstract reporting the results of the Natesto Spermatogenesis Study by the Endocrine Society for presentation at the Endocrine Society's Annual Meeting.
Jan 27, 2020 09:00 am ET
Dec 24, 2019 08:05 am ET
Aytu BioScience and Innovus Pharmaceuticals Announce Filing of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu BioScience
ENGLEWOOD, CO and SAN DIEGO, CA / ACCESSWIRE / December 24, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs and Innovus Pharmaceuticals, Inc. (OTCQB:INNV), a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer health products, today announced that the companies have filed with the U.S. Securities and Exchange Commission a registration statement on Form S-4 containing a joint preliminary proxy statement/prospectus in connection
Dec 17, 2019 11:30 pm ET
Rigrodsky & Long, P.A. Files Class Action Suit Against Aytu BioScience, Inc.
Rigrodsky & Long, P.A.: Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of Aytu BioScience, Inc. (“Aytu”) (NASDAQ GS: AYTU) common...
Dec 12, 2019 01:19 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Progenics Pharmaceuticals, Inc. (NASDAQ GS: PGNX) regarding possible breaches of fiduciary duties and other violations of law related to Progenics’ agreement to be acquired by Lantheus...
Dec 05, 2019 06:05 am ET
MiOXSYS Male Infertility Test Will be Featured in Product Symposium at the 8th Annual Congress of the German Federation of Reproductive Biology and Medicine
ENGLEWOOD, CO / ACCESSWIRE / December 5, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced that MiOXSYS® will be featured in a Product Symposium at the 8th Annual Congress of the German Federation of Reproductive Biology and Medicine held December 5-7, 2019 in Leipzig, Germany.
Dec 03, 2019 08:05 am ET
Aytu BioScience to Present at LD Micro 12th Annual Main Event Investor Conference on December 11, 2019
ENGLEWOOD, CO / ACCESSWIRE / December 3, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that Josh Disbrow, Chairman and Chief Executive Officer, and David Green, Chief Financial Officer, will present at the 12th Annual LD Micro Main Event investor conference at 9:00 am PT on December 11, 2019.
Dec 02, 2019 08:05 am ET
Aytu BioScience Announces Launch of Natesto(R) U.S. Co-Promotion with Acerus Pharmaceuticals
Acerus Launches U.S. Specialty Sales Force; Sales Team Expansion Nearly Doubles Current Natesto Sales Force
Nov 19, 2019 08:00 am ET
Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading Pharmacy Benefit Manager’s National Formulary
Provides More Than Six Million US Lives Unrestricted Access to Only FDA-Approved 12-Hour Codeine-Based Cold-Cough Syrup
Nov 14, 2019 04:01 pm ET
Aytu Reports First Quarter 2020 Financial Results
ENGLEWOOD, CO / ACCESSWIRE / November 14, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today will provide an overview of its business, including the company's operational and financial results for its fiscal first quarter 2020 that ended September 30, 2019. The company will host a live conference call and webcast today at 4:30 p.m. ET. Conference call details are provided at the end of this press release.
Nov 11, 2019 06:05 am ET
Aytu BioScience Announces Hiring of Matthew Phillips as Executive Vice President of Commercial Operations
ENGLEWOOD, CO / ACCESSWIRE / November 11, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the hiring of Matthew Phillips as the company's Executive Vice President of Commercial Operations. Mr. Phillips' hiring became effective November 8, 2019 following the recently announced acquisition of a portfolio of six prescription products from Cerecor, Inc. (the "Commercial Portfolio") and the accompanying commercial team supporti
Nov 07, 2019 08:05 am ET
Aytu BioScience to Report Fiscal Q1 FY 2020 Results and Business Update
ENGLEWOOD, CO / ACCESSWIRE / November 7, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that the company will present its operational results for the quarter ended September 30, 2019 on November 14, 2019, at 4:30 p.m. ET. The company will review accomplishments from the quarter and provide an overview of its business and growth strategy.
Nov 04, 2019 02:15 pm ET
Kaskela Law LLC Announces Stockholder Investigation of Aytu BioScience, Inc. – AYTU
Kaskela Law LLC is investigating Aytu BioScience, Inc. (“Aytu”) (NASDAQ: AYTU) on behalf of the company’s stockholders.  The investigation seeks to determine whether Aytu’s officers and/or directors violated the securities laws in connection with...
Nov 04, 2019 09:00 am ET
Aytu BioScience Announces Closing of $12.4M Prescription Product Portfolio Purchase
Asset Purchase Increases Combined Company Annual Revenue to $44M, Including Previously Announced Acquisition of Innovus Pharmaceuticals
Oct 21, 2019 07:01 am ET
Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading National Pharmacy Benefit Manager's Formulary
Tuzistra XR Now Covered on Commercial Plans Covering Over 30 Million U.S. Lives
Oct 17, 2019 08:30 am ET
Aytu BioScience Announces Positive Clinical Results from Natesto(R) Spermatogenesis Study
Phase IV, Investigator-Initiated Study is First to Conclusively Show that a Testosterone Replacement Therapy (TRT) Maintains Key Fertility Measures in Men with Low T
Oct 16, 2019 08:30 am ET
Aytu BioScience to Announce Results from Natesto(R) Spermatogenesis Study on Thursday, October 17
Investigator-initiated, Phase IV study results will be presented today at 75th Annual American Society for Reproductive Medicine (ASRM) scientific conference ‘Late Breaking' abstract session
Oct 14, 2019 06:30 am ET
Aytu BioScience Acquires $12.4 Million Prescription Product Portfolio
Transaction increases annual revenue to $44M and is expected to accelerate time to breakeven, following recently announced acquisition of Innovus Pharmaceuticals
Oct 14, 2019 06:15 am ET
Aytu BioScience Announces $10 Million Private Placement
Armistice Capital and Altium Capital jointly participated in financing

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.